PALATIN TECHNOLOGIES INC
Novel small-molecule and peptide therapeutics for inflammatory and autoimmune diseases
- Sector
- Biotech
- Headquarters
- CRANBURY, NJ
- Latest Form D
- $35M, Jul 2012
- Total capital
- $35M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $35M
- 1 Form D · last Jul 2012
- 172 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 18
- 22 pending · first 2014
- Rank in peer group#94 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$35M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#94 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Carl SpanaResearcherExecutive Officer, DirectorLinked by 2 patents
- Alan W. DuntonDirectorNamed in SEC Form D filings
- John K. A. PrendergastDirectorNamed in SEC Form D filings
- Joseph Stanley HullDirectorNamed in SEC Form D filings
- Perry B. MolinoffDirectorNamed in SEC Form D filings
- Robert K. deVeerDirectorNamed in SEC Form D filings
Show all 9 people
- Robert I. TaberDirectorNamed in SEC Form D filings
- Stephen T. WillsExecutive OfficerNamed in SEC Form D filings
- Zola P. HorovitzDirectorNamed in SEC Form D filings
What it has protected
USPTO · 18 granted of 40- PendingOrally Active Melanocortin RECEPTOR-4 CompoundsUSPTOApplication 19374698
- GrantedOrally Active Melanocortin Receptor-4 CompoundsUSPTOUS 12,459,894
- GrantedUse Of Bremelanotide In Patients With Controlled HypertensionUSPTOUS 11,590,209
Show all 40 patent records
- Orally Active Melanocortin RECEPTOR-4 CompoundsApr 30, 2026 · Application 19374698Pending
- Orally Active Melanocortin Receptor-4 CompoundsNov 4, 2025 · US 12,459,894Granted
- Use Of Bremelanotide In Patients With Controlled HypertensionFeb 28, 2023 · US 11,590,209Granted
- Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic PeptidesNov 17, 2022 · Application 17812014Pending
- Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation TherapyMar 29, 2022 · US 11,286,280Granted
- Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific DeliveryMar 24, 2022 · Application 17028437Pending
- Orally Active Melanocortin Receptor-4 CompoundsJul 1, 2021 · Application 17204549Pending
- Uses Of Bremelanotide In Therapy For Female Sexual DysfunctionMar 4, 2021 · Application 17081732Pending
- Therapies for Obesity, Diabetes and Related IndicationsSep 3, 2020 · Application 16878097Pending
- Melanocortin Receptor-Specific Peptide with C-Terminal NaphthylalanineJul 14, 2020 · US 10,711,039Granted
- Therapies For Obesity, Diabetes And Related IndicationsMay 26, 2020 · US 10,660,939Granted
- Melanocortin Receptor-Specific PeptidesApr 28, 2020 · US 10,632,171Granted
- Uses Of Bremelanotide In Therapy For Female Sexual DysfunctionJul 18, 2019 · Application 16368417Pending
- Uses of Bremelanotide in Therapy for Female Sexual DysfunctionMay 14, 2019 · US 10,286,034Granted
- Melanocortin Receptor-Specific PeptidesJan 15, 2019 · US 10,179,804Granted
- Melanocortin-1 Receptor-Specific Linear PeptidesOct 23, 2018 · US 10,106,578Granted
- Melanocortin-1 Receptor-Specific Cyclic HexapeptidesJul 10, 2018 · US 10,017,539Granted
- Uses Of Bremelanotide In Therapy For Female Sexual DysfunctionJul 11, 2017 · US 9,700,592Granted
- Replacement Therapy for Natriuretic Peptide DeficienciesMar 30, 2017 · Application 15347870Pending
- Melanocortin-1 Receptor-Specific Linear PeptidesFeb 28, 2017 · US 9,580,466Granted
- Replacement Therapy for Natriuretic Peptide DeficienciesDec 8, 2016 · Application 15214674Pending
- Melanocortin Receptor-Specific HeptapeptidesOct 4, 2016 · US 9,458,201Granted
- MELANOCORTIN-1 Receptor-specific Cyclic PeptidesSep 20, 2016 · US 9,447,148Granted
- Uses Of Bremelanotide In Therapy For Female Sexual DysfunctionMay 31, 2016 · US 9,352,013Granted
- Melanocortin-1 Receptor-Specific Cyclic PeptidesNov 4, 2014 · US 8,877,890Granted
- Uses Of Natriuretic Peptide ConstructsSep 9, 2014 · US 8,828,926Granted
- Melanocortin Receptor-Specific Peptides for Treatment of Female Sexual DysfunctionMay 20, 2014 · US 8,729,224Granted
- Pharmaceutical For Ocular IndicationsApplication PCTUS2009038024Pending
- Amino Acid Surrogates For Peptidic ConstructsApplication PCTUS2007065632Pending
- Cyclic Natriuretic Peptide ConstructsApplication PCTUS2007065645Pending
- Cyclic Peptide Isolation By Spray DryingApplication PCTUS2006033465Pending
- Melanocortin Receptor-specific Piperazine Compounds With Diamine GroupsApplication PCTUS2006031472Pending
- Melanocortin Receptor-specific Piperazine And Keto-piperazine CompoundsApplication PCTUS2006031474Pending
- Cyclic Peptides For Treatment Of CachexiaApplication PCTUS2005024138Pending
- Cyclic Peptides For Treatment Of CachexiaApplication PCTUS2005024125Pending
- Multiple Agent Therapy For Sexual DysfunctionApplication PCTUS2005018739Pending
- Cyclic Peptide Compositions And Methods For Treatment Of Sexual DysfunctionApplication PCTUS2004025749Pending
- Melanocortin Receptor-specific CompoundsApplication PCTUS2004013803Pending
- Knockout Identification Of Target-specific Sites In PeptidesApplication PCTUS2004002933Pending
- Piperazine Melanocortin-specific CompoundsApplication PCTUS2004001462Pending
Related companies, and why
- Cerium Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- KallyopeSimilar federal contract value in Biotech · null in contracts
- Ashvattha Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- BioIncept, LLCSimilar federal contract value in Biotech · null in contracts
- Diceros Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- BIOPHY, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .